Association between Sarcopenia and Overactive Bladder in Elderly Diabetic Patients

Ida, Satoshi; Kaneko, Ryutaro; Nagata, Hirohiko; Noguchi, Yoshinori; Araki, Yasuha; Nakai, Mari; Ito, Sho; Imataka, Kanako; Murata, Kazuya

doi:10.1007/s12603-019-1190-1

Cited by 5 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 198 diabetic patients, the SARC-F has been reported to be useful in predicting hospitalization and development of disability (43). In diabetic patients, the SARC-F is also useful in predicting mild cognitive impairment (44), depression (45), overactive bladder (46), and sleep disorders (47). In a study of 127 patients undergoing peritoneal dialysis, the sensitivity and specificity of SARC-F for sarcopenia assessed by AWGS2 were 0.700 and 0.812, respectively (48).…”

Section: Clinical Significance Of the Sarc-f According To Diseasesmentioning

confidence: 99%

Screening Tools for Sarcopenia

Nishikawa

Asai

Fukunishi

et al. 2021

In Vivo

View full text Add to dashboard Cite

The elderly people are characterized by multiple comorbidities, dementia, and are at risk of developing sarcopenia and frailty. Sarcopenia is defined by loss of muscle mass and muscle strength or physical decline. Sarcopenia is a main component of physical frailty. Screening tools for sarcopenia that can be easily determined in daily practice are useful and include the SARC-F screening tool. SARC-F is a questionnaire consisting of five questions: Strength (S), Assistance walking (A), Rising from a chair (R), Climbing stairs (C), and Falls (F) on a scale of 0 to 2. The recommended cutoff value is ≥4 points. The SARC-F has been shown to correlate well with clinical outcomes in the elderly and various underlying diseases, while it is also true that the SARC-F has its shortcomings such as low sensitivity for sarcopenia. In this review, we mainly outline the SARC-F and mention other screening tools for sarcopenia.The aging of Japan's population continues to accelerate (1). According to the Japanese government report, the aging rate (65 years old or older) was 15.1% of the total population in 1996, but it increased significantly to 28.4% in 2019 (2). In addition, the estimated aging rate as of January 1997 is projected to be 27.4% in 2025, but as of 2019, it has already exceeded the projection. The number of people aged 65 or older will continue to increase, and is estimated to reach 33.3% in 2036 and 38.4% in 2065. In order to improve the quality of life (QOL) of the increasing number of elderly people, efforts have been made in the fields of health, medical care, and welfare to extend healthy life expectancy (the period of time during which there are no limitations in daily life), but there are still many issues to be addressed. The elderly people are characterized by multiple comorbidities, dementia, and risk of sarcopenia and frailty (3). In 2019, the Ministry of Health, Labour and Welfare (MHLW) in Japan published the "Guidelines for Health Services Based on the Characteristics of the Elderly, Version 2", and announced the strengthening of measures against frailty, especially for elderly people aged 75 or older. The guidelines newly added the implementation of "health checkups for frailty" with the aim of integrating health guidance and care prevention. Specifically, the report has recommended the use of a "questionnaire for the elderly aged 75 or older" focusing on frailty in health checkups and other examinations conducted by municipalities since fiscal 2020. This questionnaire is expected to help prevent and raise awareness of frailty among many elderly people. Early intervention through such efforts will lead to a prolongation in healthy life expectancy. In addition, sarcopenia is a condition that forms the basis of physical frailty (4). Sarcopenia leads to decreased physical activity, and decreased physical activity leads to sarcopenia. Both are involved in frailty, forming the so-called "frailty cycle" (4). On the other hand, the number of people aged 60 or older in the world was estimated to be 600 million ...

show abstract

Section: Clinical Significance Of the Sarc-f According To Diseasesmentioning

confidence: 99%

Screening Tools for Sarcopenia

Nishikawa

Asai

Fukunishi

et al. 2021

In Vivo

View full text Add to dashboard Cite

show abstract

“…Another study investigated the association between sarcopenia and OAB in elderly patients with diabetes mellitus, revealing a significant correlation between OAB and sarcopenia. 31 However, this study did not assess muscle mass; instead, it relied on a questionnaire for diagnosing sarcopenia. In a separate study exploring the relationship between sarcopenia and OAB, researchers identified sarcopenia as an independent risk factor for OAB.…”

Section: Discussionmentioning

confidence: 99%

Impact of sarcopenia and vitamin D levels on the severity of lower urinary tract symptoms in older males

Surmeli,

Karpuzcu,

Atmis

et al. 2024

SMJ

View full text Add to dashboard Cite

Objectives: To assess the impact of sarcopenia and vitamin D levels on the severity of lower urinary tract symptoms (LUTS). Methods: A total of 193 male patients, aged 60 years and above, who visited the geriatric outpatient clinic at Ibn-i Sina Hospital in Ankara, Turkey, between December 2019 and March 2021, were enrolled. Sarcopenia was diagnosed according to the criteria set by the European Working Group on Sarcopenia in Older People. The presence and severity of lower urinary tract symptoms were assessed using the International Prostate Symptom Score questionnaire, categorizing symptom severity as mild or moderate-to-severe. Results: The median patient age was 71 years (range: 66-77). Sarcopenia affected 24.9% of the population studied. Mild LUTS was observed in 43.5% and moderate-to-severe LUTS was observed in 56.5% of patients. Sarcopenia prevalence was significantly higher in the individuals with moderate-to-severe LUTS compared to those with mild-LUTS ( p =0.021). After adjusting for Charlson comorbidity index and age, only vitamin D levels were significantly associated with increased odds of moderate-to-severe LUTS (odds ratio [OR]=0.95, 95% confidence interval [CI]: [0.92-0.98], p =0.002). Sarcopenia was not significantly associated with the severity of LUTS (OR=2.04, 95% CI: [0.94-4.45], p =0.070). An inverse linear trend was observed between quartiles of 25 (OH) vitamin D and LUTS severity. As 25 (OH)vitamin D levels increased, the proportion of patients with moderate-to-severe LUTS decreased ( p =0.023). Conclusion: Sarcopenia did not significantly impact LUTS severity, but low vitamin D levels were associated with moderate-to-severe LUTS.

show abstract

“…Several studies on women have reported an association between sarcopenia-related factors, such as reduced handgrip strength, impaired standing balance, decreased psoas muscle mass, and LUTS (urinary incontinence and OAB) [18] [19]. Ida et al showed that in male patients with diabetes, the prevalence of OAB was signi cantly higher in patients with sarcopenia screened using SARC-F [20]. Qin et al reported that low lean mass, a key indicator of muscle mass, strength and function was associated with a higher risk of LUTS in elderly men [21].…”

Section: Discussionmentioning

confidence: 99%

Screening tool for sarcopenia (SARC-F) predicts unsatisfactory medical treatment of lower urinary tract symptoms in elderly men aged 75 years or older: a preliminary observational study

Wada,

Hatakeyama,

Takagi

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose: We investigated the influence of sarcopenia on treatment outcomes in elderly patients receiving medical therapy for lower urinary tract symptoms (LUTS). Methods: We included male patients with LUTS aged ≥75 years who had not changed their medication for 1 year. Current conditions were estimated using IPSS, overactive bladder symptoms score (OABSS), and screening tool for sarcopenia (SARC-F). SARC-F score of ≧4 was defined as sarcopenia. Results: We included 59 patients in this study, including 16 patients (27.1%) with sarcopenia. IPSS total score, voiding symptom score of IPSS, and IPSS-QOL were significantly higher in the sarcopenia group than the non-sarcopenia group. The non-sarcopenia group had significantly larger PV (40 vs. 20 ml) and higher testosterone levels (497.5 vs. 369 ng/ml) compared with the sarcopenia group. Moderate and severe LUTS (IPSS total ≥8) persisted in 34 patients (57.6%) after medical treatment. Multivariate analysis showed that only SARC-F was a significant factor affecting the IPSS total ≥8 despite medical treatment for 1 year (OR 1.67, 95%CI: 1.13–2.46). Conclusion: Sarcopenia defined by using SARC-F is a significant factor for unsatisfactory medical treatment of LUTS in elderly men aged ≥75 years.

show abstract

Association between Sarcopenia and Overactive Bladder in Elderly Diabetic Patients

Cited by 5 publications

References 38 publications

Screening Tools for Sarcopenia

Screening Tools for Sarcopenia

Impact of sarcopenia and vitamin D levels on the severity of lower urinary tract symptoms in older males

Screening tool for sarcopenia (SARC-F) predicts unsatisfactory medical treatment of lower urinary tract symptoms in elderly men aged 75 years or older: a preliminary observational study

Contact Info

Product

Resources

About